'Global generic drug market to reach $221-bn by 2016'

摘要

The economic recession has been a double-edged sword for the international generic drugs business. Driven by the need to control costs, the use of generic drugs has grown considerably in recent years, even in markets where traditionally they have not been favoured. At the same time, health payers have been putting pressure on the sector to squeeze margins even tighter.